Amazon S3 on MSN
Key symptoms of an enlarged prostate: A must-read for men
Benign prostate hyperplasia (BPH) is a non-cancerous enlargement of the prostate gland, which is generally the shape and size ...
Man patients with MIBC are ineligible for or refuse SOC cisplatin. SunRISe-4 evaluated neoadjuvant gemcitabine intravesical system (TAR-200) plus cetrelimab or cetrelimab monotherapy for pathologic ...
In patients with high-risk melanoma, the personalized cancer vaccine intismeran autogene and Keytruda reduced the risk of ...
Zacks.com on MSN
CG Oncology Stock Rallies Nearly 32% in a Week: Here is Why
Shares of CG Oncology CGON, a late-stage clinical biopharmaceutical company, have surged nearly 32% over the past week. The ...
Shares of Moderna MRNA were up 15.8% on Jan. 21, after the company and its partner Merck MRK announced positive median ...
The healthcare giant just took a major step that could reshape its MedTech business and boost its dividend track record.
For individuals facing fear, uncertainty and repeated procedures associated with recurrent low-grade intermediate-risk bladder tumors, timely access to treatment can be critical. ZUSDURI, the first ...
CG Oncology develops cretostimogene via rolling BLA, phase 3 PIVOT-006 data in 1H 2026, and $680M cash into 2028. Find out why CGON stock is a strong buy.
Moderna & Merck announce 5-year data for intismeran autogene in combo with Keytruda demonstrated sustained improvement in primary endpoint of recurrence-free survival in patients with high-risk stage ...
The mental load of being a cancer patient.
Moderna and Merck shared five-year study data showing their combined cancer treatment cut the risk of melanoma coming back or ...
Intismeran autogene with pembrolizumab shows a 49% reduction in recurrence or death risk in patients with high-risk resected melanoma over 5 years. The personalized mRNA therapy targets ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results